Retrophin, Inc. | Business Contracts

Form of Pre-Funded Warrant (Filed With SEC on March 1, 2023)

Amendment No. 1 to the License and Collaboration Agreement, effective as of October 5, 2022, by and between Travere Therapeutics Switzerland GmbH (formerly known as Orphan... (Filed With SEC on February 23, 2023)

The Company's 2023 Executive Officer Annual Bonus Plan (Filed With SEC on February 23, 2023)

Amendment No. 4 to Sublicense Agreement dated as of September 17, 2015, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on February 24, 2022)

Sublicense Agreement, dated February 16, 2012, by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation, Pharmacopeia, Inc., a Delaware limited liability company,... (Filed With SEC on February 24, 2022)

Fifth Amendment to Trademark License and Supply Agreement, effective September 30, 2020, between the Company and Mission Pharmacal Company (Filed With SEC on November 5, 2020)

Office Lease, effective April 12, 2019, between the Company and Kilroy Realty, L.P (Filed With SEC on August 6, 2019)

Underwriting Agreement, dated February 28, 2023, by and among Travere Therapeutics, Inc., Jefferies LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and SVB Securities LLC (Filed With SEC on March 1, 2023)

First Amendment to Master Manufacturing Supply Agreement, effective as of November 14, 2022, between the Company and STA Pharmaceutical Hong Kong Limited, a subsidiary of WuXi... (Filed With SEC on February 23, 2023)

Employment Agreement, effective September 1, 2022, between the Company and Christopher Cline (Filed With SEC on August 17, 2022)

Non-Employee Director Compensation Program, as amended (Filed With SEC on May 5, 2022)

Retirement and Transition Agreement dated April 19, 2022, between the Company and Laura Clague (Filed With SEC on April 20, 2022)

Underwriting Agreement, dated March 8, 2022, by and among the Company, Jefferies LLC, SVB Securities LLC, BofA Securities, Inc. and Evercore Group L.L.C (Filed With SEC on March 11, 2022)

Second Supplemental Indenture, dated March 11, 2022, between the Company and U.S. Bank Trust Company, National Association, as Trustee (including the form of 2.25% Convertible... (Filed With SEC on March 11, 2022)

Commercial Supply Agreement, dated December 21, 2021, between the Company and Catalent Pharma Solutions, LLC (Filed With SEC on February 24, 2022)

Amendment No. 3 to Sublicense Agreement dated as of February 27, 2015, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on February 24, 2022)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for use under the Company's 2018 Equity Incentive Plan, as amended (Filed With SEC on February 24, 2022)

Form of Stock Option Grant Notice, Option Agreement and Exercise Notice for use under the Company's 2018 Equity Incentive Plan, as amended (Filed With SEC on February 24, 2022)

The Company's 2022 Executive Officer Annual Bonus Plan (Filed With SEC on February 24, 2022)

Description of Common Stock (Filed With SEC on February 24, 2022)

Consulting Services Agreement dated January 1, 2022, between the Company and Noah Rosenberg, M.D (Filed With SEC on January 6, 2022)

License and Collaboration Agreement, dated September 15, 2021, by and among Orphan Technologies Limited and Vifor (International) Ltd., and, solely with respect to Article 15, the... (Filed With SEC on October 29, 2021)

Transition Agreement dated October (Filed With SEC on October 12, 2021)

The Company's 2021 Executive Officer Annual Bonus Plan (Filed With SEC on March 1, 2021)

Description of Common Stock (Filed With SEC on March 1, 2021)

Underwriting Agreement, dated February 11, 2021, by and among Travere Therapeutics, Inc., BofA Securities, Inc., Jefferies LLC and SVB Leerink LLC, as representatives of the... (Filed With SEC on February 12, 2021)

Stock Purchase Agreement, dated October 21, 2020, by and among the Company, Orphan Technologies Limited and Citco Trustees (Cayman) Limited acting solely in its capacity as the... (Filed With SEC on November 18, 2020)

Master Manufacturing Supply Agreement, dated September 30, 2020, between the Company and STA Pharmaceutical Hong Kong Limited, a subsidiary of WuKi AppTec (Filed With SEC on November 5, 2020)

Underwriting Agreement, dated June 8, 2020, by and among Retrophin, Inc., Jefferies LLC, Barclays Capital Inc. and BofA Securities, Inc., as representatives of the several... (Filed With SEC on June 9, 2020)

Non-Employee Director Compensation Program, as amended (Filed With SEC on May 11, 2020)

2020 Retrophin, Inc. Executive Officer Annual Bonus Plan (Filed With SEC on May 11, 2020)

Employment Agreement, dated October 1, 2019, by and between the Company and Peter Heerma (Filed With SEC on May 11, 2020)

Non-Employee Director Compensation Program (Filed With SEC on February 24, 2020)

Description of Common Stock (Filed With SEC on February 24, 2020)

Open Market Sales Agreement, dated February 24, 2020, by and between Retrophin, Inc. and Jefferies LLC (Filed With SEC on February 24, 2020)

Separation Agreement between Retrophin Inc. and Neil McFarlane dated April 19, 2019 (Filed With SEC on April 19, 2019)

Retirement Agreement, dated January 4, 2019, by and between the Company and Stephan Aselage (Filed With SEC on February 26, 2019)

2019 Retrophin, Inc. Executive Officer Annual Bonus Plan (Filed With SEC on February 26, 2019)

Employment Agreement, dated January 4, 2019, by and between the Company and Eric M. Dube (Filed With SEC on February 26, 2019)

Employment Agreement, dated July 26, 2018, by and between the Company and Noah Rosenberg, M.D (Filed With SEC on February 26, 2019)

Fourth Amendment to Trademark License and Supply Agreement dated as of November 28, 2018, between Retrophin Inc. and Mission Pharmacal (Filed With SEC on February 26, 2019)

Retrophin, Inc. (41)